Piyarat Limpawittayakul

Dr. Piyarat Limpawittayakul


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2024 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
PLPiyarat Limpawittayakul
Piyarat Limpawittayakul
SPSupinda Petchjorm
Supinda Petchjorm
WCWorawong Chueansuwan
Worawong Chueansuwan
WBWanvisa Boonfueang
Wanvisa Boonfueang
Paclitaxel is a chemotherapeutic drug widely used in breast cancer treatment. While common side effects are possible, paclitaxel-induced pneumonitis is rare, with an estimated incidence of 1%–5% and a high mortality rate. A 57-year-old Thai woman diagnosed with stage II right breast cancer. She received adjuvant chemotherapy comprising doxorubicin and cyclophosphamide, followed by weekly paclitaxel. After the ninth paclitaxel cycle, she developed acute respiratory failure. Transbronchial biopsies revealed acute fibrinous and organizing pneumonitis. The patient was placed in prone position. Following the administration of dexamethasone, her symptoms improved. However, while reducing the dexamethasone dosage, she developed new-onset dyspnea as well as Takotsubo cardiomyopathy. Intravenous methylprednisolone 500 mg/day was administered for 3 days followed by transition to intravenous dexamethasone and slow tapering to prednisolone. Prednisolone was gradually tapered and eventually discontinued after 3 months. Paclitaxel-induced pneumonitis is a rare complication. The diagnosis should be considered in any patient who develops respiratory symptoms while receiving paclitaxel. Acute fibrinous and organizing pneumonitis is a rare type of interstitial pneumonitis with high recurrence and mortality rates. High-dose steroids are needed to treat this type of pneumonitis.

1 May 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
CSChayanee Samdaengpan
Chayanee Samdaengpan
PSPrakongboon Sungkasubun
Prakongboon Sungkasubun
WCWorawit Chaiwiriyawong
Worawit Chaiwiriyawong
ASArchara Supavavej
Archara Supavavej
JSJomtana Siripaibun
Jomtana Siripaibun
PLPiyarat Limpawittayakul
Piyarat Limpawittayakul
PURPOSE: Corticosteroids are known to diminish immune response ability, which is generally used in routine premedication for chemotherapy. The intersecting of timeframe between the corticosteroid's duration of action and peak COVID-19 vaccine efficacy could impair vaccine immunogenicity. Thus, inquiring about corticosteroids affecting the efficacy of vaccines to promote effective immunity in this population is needed. METHODS: This was a prospective longitudinal observational cohort study that enrolled patients with solid cancer classified into dexamethasone- and nondexamethasone-receiving groups. All participants were immunized with two doses of ChAdOx1 nCoV-19 or CoronaVac vaccines. This study's purpose was to compare corticosteroid's effect on immunogenicity responses to the SARS-CoV-2 S protein in patients with cancer after two doses of COVID-19 vaccine in the dexamethasone and nondexamethasone group. Secondary outcomes included the postimmunization anti–spike (S) immunoglobin G (IgG) seroconversion rate, the association of corticosteroid dosage, time duration, and immunogenicity level. RESULTS: Among the 161 enrolled patients with solid cancer, 71 and 90 were in the dexamethasone and nondexamethasone groups, respectively. The median anti–S IgG titer after COVID-19 vaccination in the dexamethasone group was lower than that in the nondexamethasone group with a statistically significant difference (47.22 v 141.09 U/mL, P = .035). The anti–S IgG seroconversion rate was also significantly lower in the dexamethasone group than in the nondexamethasone group (93.83% v 80.95%, P = .023). The lowest median anti–SARS-CoV-2 IgG titer level at 7.89 AU/mL was observed in patients with the highest dose of steroid group (≥37 mg of dexamethasone cumulative dose throughout the course of chemotherapy [per course]) and patients who were injected with COVID-19 vaccines on the same day of receiving dexamethasone, 25.41 AU/mL. CONCLUSION: Patients with solid cancer vaccinated against COVID-19 disease while receiving dexamethasone had lower immunogenicity responses than those who got vaccines without dexamethasone. The direct association between the immunogenicity level and steroid dosage, as well as length of duration from vaccination to dexamethasone, was observed.

17 August 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
PLPiyarat Limpawittayakul
Piyarat Limpawittayakul
PSPrakongboon Sungkasubun
Prakongboon Sungkasubun
WCWorawit Chaiwiriyawong
Worawit Chaiwiriyawong
ASArchara Supavavej
Archara Supavavej
BWBowon Weerasubpong
Bowon Weerasubpong
CSChayanee Samdaengpan
Chayanee Samdaengpan
Cancer patients are more vulnerable to coronavirus disease 2019 (COVID-19) owing to their compromised immune status. However, data regarding COVID-19 vaccine safety and immune response in cancer pa...

1 January 2026 in Case Reports in Medicine
Verified
Journal Article
Open access
PLPiyarat Limpawittayakul
Piyarat Limpawittayakul
NTNarongchai Teerayathanakul
Narongchai Teerayathanakul
Background: Xp11 translocation renal cell carcinoma (tRCC) is a rare and aggressive renal cancer characterized by gene fusion involving TFE3 . It accounts for < 5% of renal cancers and shows variable responses to conventional antivascular endothelial growth factor therapies. Optimal treatment strategies for metastatic cases have not been determined. Objective: To report the clinical presentation, molecular diagnosis, and therapeutic response of an adolescent patient with metastatic Xp11 tRCC treated with pembrolizumab and lenvatinib. Methods: A 17‐year‐old female presented with a large left renal mass, gross hematuria, extensive metastases to the supraclavicular, mediastinal, and intra‐abdominal lymph nodes, and pleural nodules. Immunohistochemistry confirmed transcription factor E3 (TFE3) positivity, and next‐generation sequencing identified an ASPSCR1–TFE3 fusion. Following renal embolization for local control, the patient received systemic therapy (pembrolizumab at 200 mg/dose given every 3 weeks and lenvatinib at 10 mg–20 mg/day). Results: The patient showed rapid clinical improvement, with her Eastern Cooperative Oncology Group Performance Status Scale grade improving from 3 to 1 after the initial cycles. CT imaging after the sixth cycle demonstrated a marked reduction in the size of the primary tumor and in the sizes and numbers of metastatic lesions, involved lymph nodes, and pleural nodules. The patient recovered to normal well‐being. Conclusion: Pembrolizumab combined with lenvatinib showed significant antitumor activity in an adolescent with advanced ASPSCR1 – TFE3 fusion Xp11 tRCC. These findings support the utility of molecular profiling of renal tumors in young adults and suggest that this combination is an effective treatment option for this subtype of renal cancer.

4 October 2023 in Research Square
Verified
Preprint
Open access
PDF file
PLPiyarat Limpawittayakul
Piyarat Limpawittayakul
SPSupinda Petchjorm
Supinda Petchjorm
WCWorawong Chueansuwan
Worawong Chueansuwan
WBWanvisa Boonfueang
Wanvisa Boonfueang
Background: Paclitaxel is a chemotherapeutic drug widely used in breast cancer treatment. While common side effects are possible, paclitaxel-induced pneumonitis is rare, with an estimated incidence of 1%–5% and a high mortality rate. Case presentation: A 57-year-old Thai woman was diagnosed with stage II right breast cancer. She received adjuvant chemotherapy comprising doxorubicin and cyclophosphamide, followed by weekly paclitaxel. After the ninth paclitaxel cycle, she developed progressive dyspnea and acute respiratory failure. Empirical antibiotic therapy with meropenem, levofloxacin, oseltamivir, and trimethoprim-sulfamethoxazole was initiated to address potential bacterial/viral pneumonias and Pneumocystis carinii pneumonia. Transbronchial biopsies revealed acute fibrinous and organizing pneumonitis. The patient was placed in the prone position, and a muscle relaxant was administered. Following the administration of dexamethasone, her symptoms improved. However, while reducing the dexamethasone dosage, she developed new-onset dyspnea as well as tachy-brady arrhythmia and hypotension. Echocardiography revealed Takotsubo cardiomyopathy (stress-induced cardiomyopathy). Intravenous methylprednisolone 500 mg/day was administered for 3 days followed by transition to intravenous dexamethasone and slow tapering to prednisolone. Prednisolone was gradually tapered and eventually discontinued after 3 months. Discussion and Conclusions: Paclitaxel-induced pneumonitis is a rare complication. The diagnosis should be considered in any patient who develops respiratory symptoms while receiving paclitaxel. Acute fibrinous and organizing pneumonitis is a rare type of interstitial pneumonitis with high recurrence and mortality rates. High-dose steroids are needed to treat this type of pneumonitis.